biosynthesis is an effective therapeutic approach for OA. 4 Apple procyanidins are promising food components that inhibit OA progression by promoting mitochondrial biogenesis and proteoglycan homoeostasis with the up-regulation of Aggrecan in primary chondrocytes. 5 FoxO transcription factors modulate proteoglycan in cartilage homoeostasis and OA, protecting against OA-associated cartilage damage. 6 Suramin increases cartilage proteoglycan accumulation in vitro and protects against joint damage triggered by papain injection in mouse knees in vivo. 7 As one of three subtypes of peroxisome proliferator-activated receptors (PPARs, including PPARα，PPARβ/δ and PPARγ), PPARα responds to specific ligands by altering gene expression to regulate lipid and lipoprotein metabolism, apoptosis and inflammatory responses in the liver and other organs of the human body. [8] [9] [10] Some studies have reported that PPARα plays an important role in chondrocyte metabolism. Activation of PPARs α, β/δ and γ impairs TGF-β1-induced collagen production and modulates the TIMP-1/MMPs balance in three-dimensional cultured chondrocytes. 11 Agonists of PPARα, β/δ and γ reduce TGF-β1-induced proteoglycans' production in chondrocytes. 12 PPARα down-regulates AGE-induced TGF-β and MMP-9 expression in chondrocytes. 13 PPARα activation pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. 14 
In 2011, Clockaerts et al report that
PPARα activation by its agonist, WY14643, decreases inflammatory and destructive responses in OA cartilage, although it does not have an effect on COL2A1 or Aggrecan mRNA expression. 15 These studies indicate that PPARα activation may have a protective effect on articular cartilage against OA progression.
Autophagy is a highly conserved homoeostatic process, maintaining cellular homoeostasis by sequestering and degrading cytosolic macromolecules, damaged organelles and some pathogens. 16 Moreover, the relationship between PPARα and autophagy and its effect on cell metabolism have been reported. 9, [17] [18] [19] TAK1 regulates hepatic lipid metabolism and tumorigenesis via the AMPK/ mTORC1 axis, affecting both autophagy and PPARα activity. 17 Inhibition of glycogen synthase kinase 3β promotes autophagy to protect mice from acute liver failure (ALF) mediated by PPARα. 18 PPARα-mediated induction of autophagy ameliorates liver injury in cases of ALF by attenuating inflammatory responses, indicating a potential therapeutic application for ALF treatment. 9 Pharmacologic activation of PPARα reverses the normal suppression of autophagy in the fed state, inducing autophagic lipid degradation, or lipophagy. 19 These studies demonstrate that PPARα could induce autophagy to protect liver against pathological damage. Lots of evidence indicates that autophagy also participates in OA pathological progression and the enhancement of autophagy could protect articular cartilage from OA progression. [20] [21] [22] [23] For example, autophagy is a protective mechanism in normal cartilage, and its ageing-related loss is linked with cell death and OA. 20 Autophagy activation by rapamycin and Torin 1 reduces severity of experimental OA. [21] [22] [23] However, whether PPARα might regulate autophagy to protect cartilage against OA pathological progression is not determined.
In this study, we detected the effect of PPARα activation by its agonist WY14643 on autophagy and proteoglycan synthesis in 
| MATERIAL S AND ME THODS

| Reagents and antibodies
Antibodies against PPARα, ADAMTS5 and P62 were purchased 
| Mouse chondrocyte isolation and culture
Chondrocytes of knee cartilage were isolated from neonatal male 
| Western blotting analysis
Protein extracts were subjected to SDS-PAGE (8%-12%) and transferred to a PVDF membrane (GE Healthcare, Herfordshire, UK) as previously described. 26, 27 The membrane was incubated with various primary antibodies as required at 4°C overnight, followed by the addition of the corresponding secondary antibodies at room temperature for 1-2 hours. An enhanced chemiluminescence detection kit was used to detect antibody reactivity (Pierce, Rockford, IL, USA).
| Established mouse model of experimental OA
Six-week-old male mice (average weight 28 g) were acclimatized to the laboratory environment for 2 weeks before the following experiments.
Mouse joints were randomly divided into four groups (16 mice, 32 knee joints), including sham (four mice, eight knee joints), control (OA, four mice, eight knee joints), OA+DMSO (four mice, eight knee joints), and OA+WY14643 (four mice, eight knee joints). The mouse experimental model of OA was induced by DMM as previously described.
28
After the first week post-surgery, DMSO and WY14643 (5 × 10 −3 g/ kg) were intra-articularly injected once every 3 days, respectively, and mice were not killed until 4 weeks after injection. The protocol was approved by the committee on the Ethics of Animal Experiments of Xiamen University (ID no. 20170301).
| Histopathological scores
The fresh samples were fixed in 4% paraformaldehyde for 48 hours followed by decalcification in 10% EDTA-2Na for 3 weeks, and then paraffin-embedded. Three-micrometre-thick sections of the samples were cut in sagittal plane from the medial side of joint and were stained by Safranin O-Fast green stain. The articular cartilage thickness in medial femur condyle and tibial plateau (from superficial zone to subchondral bone) was measured using Image-Pro Plus 6.0 software by the two blinded observers. The degree of articular cartilage degeneration was then assessed using the OARSI histopathology assessment system. 29 Grade 0 in OARSI system represents normal cartilage and increasing grade (from 1 to 6) indicates a more biologically cartilage degeneration.
| Immunohistochemistry assay
Three-micrometre-thick sections were obtained from the paraffin-embedded specimens prior to immunohistochemistry assay.
According to the manufacturer's instruction (MAIXIN.BIO, 
| Statistics analysis
Data were presented as means ± SEM at least three separate experiments for each group. After a test for normal distribution and
Variance homogeneity detection, differences between the groups were examined for statistical significance using one-way analysis of variance following Tukey's post hoc tests with GraphPad Prism ver- 
| AKT and ERK were involved in autophagy enhancement and proteoglycan synthesis by WY14643-stimulated PPARα activation in LPStreated mouse articular chondrocytes
As shown in Figure 2A 
| Intra-articular injection of WY14643 enhanced autophagy in a mouse OA model
As shown in Figure 5A , the LC3B expression level in either OA or OA+DMSO group was lower than Sham and OA+WY14643
groups. Compared with OA+DMSO group, intra-articular
F I G U R E 2 Effect of PPARα activation by WY14643 on Akt and ERK expression in LPS-treated mouse articular chondrocytes. A. Cells
were pre-treated with LPS (0.5 μg/mL) for 2 h prior to the treatment of WY14643 (0, 50, 100 μmol/L) for 24 h. Akt, p-Akt, ERK, p-ERK and β-actin protein levels were detected via Western blotting. B. Cells were pre-treated with LPS (0.5 μg/mL) for 2 h prior to the treatment of WY14643 (50 μmol/L) with or without TCN (10 μmol/L) for 24 h. Aggrecan, ADAMTS5, LC3B, P62, Akt, p-Akt and β-actin protein levels were detected via Western blotting. C. Cells were pre-treated with LPS (0.5 μg/mL) for 2 h prior to the treatment of WY14643 (50 μmol/L) with or without PD98059 (10 μmol/L) for 24 h. Aggrecan, ADAMTS5, LC3B, P62, ERK, p-ERK and β-actin protein levels were detected via Western blotting. The data are reported as the means ± SEM of three or five independent experiments (*P < 0.05) 
| Intra-articular injection of WY14643 enhanced p-AKT and p-ERK in a mouse OA model
As shown in Figure 6A 
| D ISCUSS I ON
Our findings demonstrate that PPARα activation by WY14643 pro- The positively regulatory effect of PPARα activation on Akt phosphorylation has previously been reported. PPARα activation protects the type 2 diabetic rat myocardium against ischaemiareperfusion injury via the activation of the PI3K/Akt and nitric oxide pathway. 33 An enhanced Akt phosphorylation is observed in the ischaemic myocardium of WY14643-treated rats. 34 We also observed that WY14643 promoted Akt phosphorylation concomitant with proteoglycan synthesis in LPS-treated chondrocyte model, while Akt inhibitor, TCN, reversed the effect of WY14643 on proteoglycan synthesis. Therefore, in LPS-treated chondrocyte (mimicking OA chondrocyte), it is suggested that PPARα activation by WY14643 promoted proteoglycan synthesis by increasing Akt phosphorylation.
As a key regulator of mTOR (a suppressor of autophagy), Akt is always also considered to be an autophagy suppressor. For example, sucrose induces autophagy via inhibiting Akt/mTOR pathway in human chondrocytes. 35 In OA human cartilage, increased PTEN However, Lu et al report that rasfonin enhances autophagy with a concomitant down-regulation of mTORC1 signalling and up-regulation of Akt activity via glycolytic pathway. 37 In this study, we also found that WY14643 induced autophagy concomitant with the elevation of Akt phosphorylation. TCN, an Akt inhibitor, partially reduced WY14643-induced autophagy. It might be due to the effect of one of the upstream regulators of Akt, the class IA phosphatidylinositol 3-kinase p110-β subunit, which has been reported to be a positive regulator of autophagy. 38 Hence, Akt might not consistently function as an autophagy suppressor and regulate autophagy in a context-dependent manner, 37 and it is conceivable that Akt activation could promote autophagy induction in WY14643-treated OA chondrocytes. 48 In erosive hand OA patients, fenofibrate treatment was associated with significant decreases in pain score, tender joint count, duration of morning stiffness, disease activity score, Cochin index and ESR. 49 In this study, we found that WY14643 ameliorated cartilage degeneration in a mouse OA model concomitant with autophagy enhancement.
Similarly, WY14643 inhibits LPS-induced inflammation in syno-
vial fibroblasts via NF-kB pathway 32 and inhibits the inflammatory and destructive responses in human OA cartilage explants. 15 Hence, WY14643 may also ameliorate OA symptoms like other PPARα agonists.
In conclusion, PPARα activation by WY14643 could promote chondrocyte proteoglycan synthesis via the enhancement of autophagy involving Akt and ERK phosphorylation, exhibiting an effective chondroprotection on articular cartilage in OA pathological progression ( Figure 7) .
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